Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

ARS Pharmaceuticals, Inc

Healthcare US SPRY

10.735USD
0.46(4.43%)

Last update at 2026-06-24T15:47:00Z

Day Range

10.4110.87
LowHigh

52 Week Range

2.5511.27
LowHigh

Fundamentals

  • Previous Close 10.28
  • Market Cap870.12M
  • Volume590363
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-61.93500M
  • Revenue TTM0.01000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 1.32M
  • Diluted EPS TTM-0.52

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -54.36500M -34.68200M -20.24300M -1.06500M -23.96700M
Minority interest - - - - -
Net income -54.36500M -33.98800M -20.24300M -1.06500M -23.96700M
Selling general administrative 47.28M 18.46M 4.69M 4.23M -
Selling and marketing expenses 0.07M - - - -
Gross profit -0.04300M -16.00400M -14.76700M 3.77M -1.54600M
Reconciled depreciation 0.36M 0.32M 0.00600M 0.00600M -
Ebit -67.52000M -35.51600M -19.45400M -0.46900M -24.06700M
Ebitda -67.44700M -35.05700M -19.44800M -0.46300M -22.52100M
Depreciation and amortization 0.07M 0.46M 0.00600M 0.00600M 1.55M
Non operating income net other - 0.83M - - -
Operating income -67.52000M -35.51600M -19.45400M -0.46900M -24.06700M
Other operating expenses 67.55M 36.83M 24.96M 18.30M 24.07M
Interest expense - 0.83M 0.11M 0.03M -
Tax provision - - - - -
Interest income - - - - -
Net interest income - - - - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - -0.69400M 0.79M 0.60M -
Total revenue 0.03M 1.32M 5.51M 17.84M -
Total operating expenses 67.48M 36.83M 24.96M 18.30M 22.52M
Cost of revenue 0.07M 17.32M 20.27M 14.07M 1.55M
Total other income expense net 13.15M 0.83M -0.78900M -0.59600M 0.10M
Discontinued operations - - - - -
Net income from continuing ops -61.62600M -34.68200M -20.24300M -1.06500M -
Net income applicable to common shares - -34.68200M -20.24300M -1.06500M -
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 233.19M 281.44M 61.45M 26.41M 15.65M
Intangible assets 0.62M - - - -
Earning assets - - - - -
Other current assets 2.41M 3.32M 7.45M 1.48M 0.55M
Total liab 2.43M 8.55M 92.72M 40.46M 21.25M
Total stockholder equity 230.76M 272.89M -31.26900M -14.05200M -5.60300M
Deferred long term liab - - - - -
Other current liab 1.39M 3.27M 1.32M 0.92M 2.11M
Common stock 0.01000M 0.00900M 0.26M 0.22M -
Capital stock 0.01000M 0.00900M 0.26M 0.22M -
Retained earnings -131.30300M -76.93800M -42.25600M -22.01300M -63.78700M
Other liab - 2.85M 3.08M 3.56M -
Good will - - - - -
Other assets - 2.96M 0.02M 0.00200M -
Cash 70.97M 210.52M 60.06M 24.52M 9.98M
Cash and equivalents - - - - -
Total current liabilities 2.39M 5.44M 8.19M 8.21M 17.93M
Current deferred revenue 0.00400M 0.28M 1.46M 3.52M -
Net debt -70.69700M -210.03700M -51.03000M -14.50300M 5.64M
Short term debt 0.24M 0.23M 3.62M 2.56M 12.30M
Short long term debt - - 3.48M 2.56M -
Short long term debt total 0.27M 0.48M 9.03M 10.02M 15.62M
Other stockholder equity 128.82M 67.97M 10.73M 7.74M 5.01M
Property plant equipment - 0.33M 0.69M 0.02M -
Total current assets 231.56M 277.70M 60.73M 26.38M 10.53M
Long term investments - - - - -
Net tangible assets - 272.89M -31.26900M -14.05200M -
Short term investments 157.39M 63.86M - - -
Net receivables 0.80M 1.01M 0.00100M 0.38M -
Long term debt - - 4.93M 7.46M -
Inventory - -1.00900M -6.78100M - -
Accounts payable 0.76M 1.66M 1.79M 1.22M 3.52M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.05M 0.41M -0.32600M - -
Additional paid in capital - - - - -
Common stock total equity - 0.00900M - - -
Preferred stock total equity - - - - -
Retained earnings total equity - -76.93800M - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.18M 2.96M -64.75700M 0.00200M -
Deferred long term asset charges - - - - -
Non current assets total 1.62M 3.73M 0.72M 0.03M 5.12M
Capital lease obligations 0.27M 0.48M 0.62M 0.00000M -
Long term debt total - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -113.34500M 63.47M -0.05500M 0.00000M -
Change to liabilities - -10.28500M -1.53300M 8.15M -
Total cashflows from investing activities - -0.19900M -0.05500M -0.05500M -
Net borrowings - -8.68100M -1.81700M 5.00M -
Total cash from financing activities 6.90M 190.73M 53.16M 5.10M 8.61M
Change to operating activities - -1.15300M 1.18M -1.68500M -
Net income -54.36500M -34.68200M -20.24300M -1.06500M -23.96700M
Change in cash -139.54700M 150.46M 35.54M 14.17M -10.18400M
Begin period cash flow 210.52M 60.06M 24.52M 10.35M 20.16M
End period cash flow 70.97M 210.52M 60.06M 24.52M 9.98M
Total cash from operating activities -59.26600M -40.07800M -17.56100M 9.07M -18.89800M
Issuance of capital stock - 0.00000M 54.81M 0.00000M -
Depreciation 0.07M 0.32M 0.00600M 0.00600M 1.55M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - 0.57M - - -
Other cashflows from financing activities 6.90M 198.84M 53.16M -403.40700M -0.09600M
Change to netincome - 7.04M 3.03M 3.66M -
Capital expenditures 0.17M 0.20M 0.06M 0.92M 0.10M
Change receivables - - - - -
Cash flows other operating - -2.46900M - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - 150.46M - - -
Change in working capital -7.33100M -12.75400M -0.35600M 6.46M 3.30M
Stock based compensation 9.23M 5.84M 2.83M 3.54M -
Other non cash items -9.65500M 1.20M 0.21M 0.12M -0.69900M
Free cash flow -59.44100M -40.27700M -17.61600M 8.15M -18.99400M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
SPRY
ARS Pharmaceuticals, Inc		 0.46 4.43% 10.73 - - 29014.82 3.77 21379.77 -9.4993
NVO
Novo Nordisk A/S		 0.09 0.19% 47.51 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 46.84 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 7.91 1.69% 476.32 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 3.79 0.61% 621.82 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

ARS Pharmaceuticals, Inc

11682 El Camino Real, San Diego, CA, United States, 92130

Key Executives

Name Title Year Born
Mr. Richard Lowenthal M.B.A., M.S., MSMSEL Founder, Pres, CEO & Director 1966
Dr. Sarina Tanimoto M.B.A., M.D. Co-Founder & Chief Medical Officer 1968
Dr. Robert Bell Ph.D. Co-Founder & Chief Science Officer NA
Ms. Kathleen D. Scott CPA Chief Financial Officer NA
Mr. Brian T. Dorsey M.S. SVP of Operations & Project Management NA
Mr. Daniel Relovsky Sr. VP of Marketing NA
Mr. Harris Kaplan M.B.A., MBA Exec. VP of Commercial Strategy 1952
Mr. Eric Karas Chief Commercial Officer 1972
Mr. Justin Chakma Chief Bus. Officer & Sec. 1989
Mr. Richard Lowenthal M.B.A., M.S., MSMSEL Founder, President, CEO & Director 1966

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.